Saturday 17 October 2026
Export VERA’s income statement to Excel — free account
Vera Therapeutics, Inc.
VERA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 26.7%, free cash flow fell 82.5% and total debt rose 1.03%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.88
0.69
−2.42%
Follow VERA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
13.64 | 25.67 | 7.71 | 4.91 | 10.73 | 22.55 | 3.36 | — |
Net Debt/EBITDA |
2.00 | 3.37 | 1.04 | 0.98 | 2.18 | 1.03 | 0.28 | — |
Debt/Assets |
10.19% | 7.73% | 28.41% | 18.88% | 5.88% | 0.00% | 0.19% | 0.00% |
Debt/Equity |
0.12 | 0.09 | 0.49 | 0.32 | 0.07 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.80 | 0.89 | 0.96 | 0.76 | 0.73 | 0.65 | 0.87 | — |
Capex/Depreciation |
0.14 | 0.12 | 0.02 | 0.07 | (28.41) | (0.17) | (0.25) | — |
Interest Coverage |
(41.89) | (21.92) | (26.94) | (91.64) | (1,720.10) | (314.70) | (234.53) | — |
| (50.71%) | (44.83%) | (107.50%) | (121.58%) | 330.12% | 84.85% | 18.83% | — | |
| (43.10%) | (36.61%) | (62.54%) | (82.77%) | (47.16%) | (178.24%) | (440.59%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (2,065.09%) | — |
Return on Tangible Assets |
(44.27%) | (24.27%) | (64.07%) | (88.92%) | (43.57%) | (103.00%) | (304.03%) | — |
Average Days of Receivables |
— | — | — | — | — | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(3.76) | (2.45) | (2.16) | (2.55) | (2.14) | (108.91) | (35.27) | — |
Cash per Share |
11.12 | 11.58 | 3.76 | 4.32 | 5.93 | 167.83 | 10.82 | — |
Shareholders Equity per Share |
9.41 | 10.43 | 2.38 | 2.89 | 5.18 | 156.96 | 12.01 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
9.41 | 10.43 | 2.38 | 2.89 | 5.18 | 156.96 | 12.01 | — |
Free Cash Flow |
(241.73) | (135.65) | (92.24) | (67.66) | (28.71) | (34.85) | (10.41) | — |
Working Capital |
675.43 | 625.85 | 149.72 | 100.10 | 74.85 | 51.86 | 2.51 | — |
Capital Expenditures |
(0.63) | (0.97) | (0.06) | (0.06) | (5.00) | (0.04) | (0.12) | — |
Net Current Asset Value |
598.67 | 572.69 | 98.16 | 71.17 | 68.38 | 49.94 | 1.73 | — |
| Other line items | ||||||||
Quick Ratio |
13.37 | 25.26 | 7.21 | 4.48 | 10.36 | 22.32 | 3.01 | — |
Depreciation/Fixed assets |
(3.39) | (8.39) | (44.41) | (16.59) | 0.00 | 0.00 | 0.37 | — |
Cash ROIC |
(17.34%) | (10.69%) | (29.54%) | (31.27%) | (18.62%) | (33.53%) | (154.24%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(3.75) | (2.43) | (2.16) | (2.54) | (1.76) | (108.78) | (34.84) | — |
Capex per Share |
(0.01) | (0.02) | 0.00 | 0.00 | (0.37) | (0.13) | (0.42) | — |
Average Payables |
14.78 | 9.39 | 11.55 | 6.69 | 1.15 | 0.63 | 0.63 | — |
Average Assets |
695.21 | 415.61 | 153.49 | 107.59 | 69.15 | 29.97 | 2.69 | — |
Average Common Equity |
590.84 | 339.42 | 89.30 | 73.25 | (9.88) | (62.95) | (62.95) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates